Co-Diagnostics Free Cash Flow (FCF) History (CODX)
Co-Diagnostics reported −$29.8M in free cash flow for fiscal 2025, an increase of $66,423 from the previous fiscal year, with a free cash flow margin of −4793.17%.
View full Co-Diagnostics company overviewCo-Diagnostics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$29.8M | $66,423 | — | −4793.17% |
| 2024 | 2024-12-31 | −$29.9M | −$6.5M | — | −763.78% |
| 2023 | 2023-12-31 | −$23.4M | −$28.6M | — | −344.20% |
| 2022 | 2022-12-31 | $5.1M | −$35.3M | −87.28% | +15.02% |
| 2021 | 2021-12-31 | $40.4M | $13.0M | +47.54% | +41.28% |
| 2020 | 2020-12-31 | $27.4M | $33.0M | — | +36.74% |
| 2019 | 2019-12-31 | −$5.6M | −$1.5M | — | −2622.80% |
| 2018 | 2018-12-31 | −$4.1M | −$780,665 | — | −10326.41% |
| 2017 | 2017-12-31 | −$3.3M | −$2.0M | — | −43600.98% |
| 2016 | 2016-12-31 | −$1.3M | — | — | — |
Co-Diagnostics quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$7.2M | $1.5M | — | −4316.67% |
| Q1 2026 | 2026-03-31 | −$8.0M | $848,834 | — | −5473.16% |
| Q4 2025 | 2025-12-31 | −$6.3M | $2.0M | — | −2398.92% |
| Q3 2025 | 2025-09-30 | −$6.0M | $1.4M | — | −4113.14% |
| Q2 2025 | 2025-06-30 | −$8.7M | −$3.4M | — | −5333.55% |
| Q1 2025 | 2025-03-31 | −$8.8M | $55,500 | — | −17576.88% |
| Q4 2024 | 2024-12-31 | −$8.3M | −$3.1M | — | −5561.02% |
| Q3 2024 | 2024-09-30 | −$7.4M | −$1.4M | — | −1154.81% |
| Q2 2024 | 2024-06-30 | −$5.3M | $801,917 | — | −199.59% |
| Q1 2024 | 2024-03-31 | −$8.9M | −$2.8M | — | −1900.73% |
| Q4 2023 | 2023-12-31 | −$5.2M | −$940,117 | — | −147.48% |
| Q3 2023 | 2023-09-30 | −$6.0M | −$6.9M | — | −244.26% |
| Q2 2023 | 2023-06-30 | −$6.1M | −$7.3M | — | −3086.23% |
| Q1 2023 | 2023-03-31 | −$6.1M | −$13.5M | — | −1012.94% |
| Q4 2022 | 2022-12-31 | −$4.3M | −$9.1M | — | −307.04% |
| Q3 2022 | 2022-09-30 | $888,274 | −$10.5M | −92.17% | +17.44% |
| Q2 2022 | 2022-06-30 | $1.1M | −$11.0M | −90.59% | +22.83% |
| Q1 2022 | 2022-03-31 | $7.4M | −$4.7M | −38.92% | +32.64% |
| Q4 2021 | 2021-12-31 | $4.8M | −$14.7M | −75.59% | +23.32% |
| Q3 2021 | 2021-09-30 | $11.3M | $2.9M | +34.15% | +37.68% |
| Q2 2021 | 2021-06-30 | $12.2M | $11.3M | +1280.91% | +44.53% |
| Q1 2021 | 2021-03-31 | $12.1M | $13.6M | — | +60.58% |
| Q4 2020 | 2020-12-31 | $19.5M | $20.7M | — | +71.80% |
| Q3 2020 | 2020-09-30 | $8.5M | $9.5M | — | +38.75% |
| Q2 2020 | 2020-06-30 | $882,149 | $2.1M | — | +3.67% |
| Q1 2020 | 2020-03-31 | −$1.4M | −$467,923 | — | −92.73% |
| Q3 2019 | 2019-09-30 | −$1.2M | −$261,198 | — | −2991.29% |
| Q4 2018 | 2018-12-31 | −$999,471 | $31,313 | — | −9234.69% |
| Q3 2018 | 2018-09-30 | −$1.2M | $364,621 | — | −12274.05% |
| Q2 2018 | 2018-06-30 | −$967,975 | −$673,547 | — | −9983.24% |
| Q1 2018 | 2018-03-31 | −$978,212 | −$517,430 | — | −10088.82% |
| Q4 2017 | 2017-12-31 | −$1.0M | −$732,729 | — | — |
| Q3 2017 | 2017-09-30 | −$1.6M | — | — | −59842.69% |
| Q2 2017 | 2017-06-30 | −$294,428 | — | — | −11939.50% |
| Q1 2017 | 2017-03-31 | −$460,782 | — | — | — |
| Q3 2016 | 2016-09-30 | −$298,055 | — | — | — |
Co-Diagnostics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $27.4M to −$29.8M, a net decrease of $57.2M. Co-Diagnostics's latest reported quarter, Q2 2026, generated −$7.2M in free cash flow, an increase of $1.5M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Co-Diagnostics filings at SEC.gov ↗